Influence of disease phase on embitterment and emotional dysregulation in psoriatic patients
V Almeida1,2, D Constante1, A Leite1
1Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, CESPU , Gandra, Portugal.
Abstract:
This study aimed to evaluate the psychosocial differences between patients with psoriasis in different phases of the disease. Seventy-one patients in exacerbation and 83 in remission were evaluated regarding sociodemographic, clinical and psychological variables, on the premise that the visibility of lesions (exacerbation phase) may impact the emotional regulation and embitterment. A regression analysis was performed to identify the variables that contribute to explain embitterment: a diagnosis of anxiety and/or depression and psoriasis severity are the identified ones. The results point to higher values of emotional dysregulation and embitterment, as well as more critical clinical variables in patients with active disease, namely, alcohol and coffee consumption, smoking and less satisfaction with current treatment, more diagnoses and more family history of anxiety and depression, more psychology/psychiatry consultations and more use of anxiolytics and antidepressants. However, only the results referring to alcohol consumption and embitterment are significantly higher in subjects in the exacerbation phase of the disease. Particular clinical attention should be provided to patients in exacerbation phase regarding psychotherapeutic approach.
Related Concept Videos
Socioemotional Development during Infancy
Primary Temperament Types
Psychological and Sociocultural Causes of Schizophrenia
Nephrotic Syndrome III : Nursing Management
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Factors Affecting Perception
An illustrative example of a perceptual set is the scenario where an airline pilot told...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment


